This cancer hunter could help make America healthy again ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏




 

_You are receiving this email because you are subscribed to MORNING
WATCHLIST FROM BEHIND THE MARKETS. If you no longer wish to receive
these partner emails, please unsubscribe
[[link removed]]
here. This message is from The Investment Journal._

-------------------------

[the investment journal]
[[link removed]]

Dear Investor,

A little known NASDAQ-listed biotech company has developed a
breakthrough medical treatment that harnesses the body’s own immune
system to fight cancer.

This “Cancer Hunter,” as I call it, could revolutionize cancer
care around the world.

And when this breakthrough hits the headlines, it could turn
little-known GT BIOPHARMA (NASDAQ: GTBP
[[link removed]]) into
a big winner for investors who jump on its undervalued stock now.

I’ll tell you more about this exciting company in a moment, but
first, please allow me to introduce myself. 

My name is Jason Williams. I’m a former Wall Street investment
banking analyst who now helps regular folks access the kinds of
opportunities my wealthy former clients take for granted.

I do this via my newsletter, _Future Giants_ — one of the top
investment newsletters in the country.

Thousands of investors follow my research as I dig deep to uncover
overlooked, fast-growing microcap companies poised to disrupt and
dominate their industries…

…and potentially bring them big profits.

Across my newsletters, subscribers have seen opportunities for gains
with companies such as:

•   Innovative Industrial Properties, which jumped 1,037%
•   SoundHound AI, which shot up 1,168%
•   Super Micro Computer, which soared 3,399%
•   NVIDIA, which exploded upwards 4,016%

And now my analysis shows that GT BIOPHARMA (NASDAQ: GTBP
[[link removed]]) could
be my next big winner.

I am blown away by the company’s breakthrough cancer therapy. It
turns the body’s natural killer cells — white blood cells that
automatically recognize and eliminate threats — into programmable,
tumor-seeking assassins.

In early human studies, the company’s first-generation therapy
achieved a 63.6% reduction in bone marrow blast levels. And the only
reported side effect was a mild fever (easily treated with Tylenol).

That’s a stunning success rate considering that most cancer drugs
are considered successful if they show a 20%–30% response rate with
tolerable toxicity.

Now, the company’s second-generation candidate, GTB-3650, is in
human clinical trials targeting two of the most aggressive and deadly
blood cancers known.

However, that’s just the beginning of all I have to tell you about
this remarkable company and its revolutionary cancer fighting
breakthrough. 

You’ll find my full analysis in a Special Report I completed
recently, where I reveal all the  reasons why GT BIOPHARMA (NASDAQ:
GTBP
[[link removed]]) could
be a great investment opportunity for you.

The Report is called _The Cancer Hunter: How One Tiny Company Could
Lead the Next Biotech Boom._ It’s a $999-value, and it’s yours
FREE with no obligation when you CLICK HERE
[[link removed]] to
claim your copy right now.

However, please don’t delay. I’m encouraging my _Future
Giants _subscribers to get in early on GT Biopharma (NASDAQ:
GTBP) so they can maximize their potential profits.

CLICK HERE
[[link removed]] to
claim your free Special Report today.


[[link removed]]

Download Free Report
[[link removed]]


To your wealth,

Jason Williams
EDITOR, _FUTURE GIANTS_

IMPORTANT NOTICE AND DISCLAIMER: All investments are subject to risk,
which must be considered on an individual basis before making any
investment decision. This paid advertisement includes a stock profile
of GT Biopharma, Inc. (Nasdaq: GTBP). Future Giants is an investment
newsletter being advertised herein. This paid advertisement is
intended solely for information and educational purposes and is not to
be construed under any circumstances as an offer to sell or a
solicitation of an offer to purchase any securities. In an effort to
enhance public awareness, GT Biopharma, Inc. (Nasdaq: GTBP) is the
sole source of funds for a budget of approximately $4,276,790 provided
to the advertising agency to cover the costs associated with creating,
printing and distribution of this advertisement. Future Giants may
receive subscription revenue in the future from new subscribers as a
result of this advertisement for its newsletter. Future Giants has not
and will not receive compensation from GT Biopharma, Inc. (Nasdaq:
GTBP) for providing this report. The advertising agency will retain
any excess sums after all expenses are paid. While this advertisement
is being disseminated and for a period of not less than 90 days
thereafter, Future Giants, the advertising agency, and their
respective officers, principals, or affiliates will not sell
securities of GT Biopharma, Inc. (Nasdaq: GTBP). If successful, this
advertisement will increase investor and market awareness of GT
Biopharma, Inc. (Nasdaq: GTBP) and its securities, which may result in
an increased number of shareholders owning and trading the securities,
increased trading volume, and possibly an increase in share price,
which may be temporary. This advertisement, the advertising agency and
Future Giants do not purport to provide a complete analysis of GT
Biopharma, Inc. (Nasdaq: GTBP) or its financial position. They are
not, and do not purport to be, broker-dealers or registered investment
advisors. This advertisement is not, and should not be construed to
be, personalized investment advice directed to or appropriate for any
particular investor. Any investment should be made only after
consulting a registered broker-dealer or registered investment advisor
or, at a minimum, doing your own research if you do not utilize an
investment professional to make decisions on what securities to buy
and sell, and only after reviewing the financial statements and other
pertinent publicly-available information about GT Biopharma, Inc.
(Nasdaq: GTBP). Further, readers are specifically urged to read and
carefully consider the Risk Factors identified and discussed in GT
Biopharma, Inc. (Nasdaq: GTBP) SEC filings. Investing in microcap
securities such as GT Biopharma, Inc. (Nasdaq: GTBP) is speculative
and carries a high degree of risk. Past performance does not guarantee
future results. This advertisement is based exclusively on information
generally available to the public and does not contain any material,
non-public information. The information on which it is based is
believed to be reliable. Nevertheless, the advertising agency and
Future Giants cannot guarantee the accuracy or completeness of the
information and are not responsible for any errors or omissions. This
advertisement contains forward-looking statements, including
statements regarding expected continual growth of GT Biopharma, Inc.
(Nasdaq: GTBP) and/or its industry. The advertising agency and Future
Giants note that statements contained herein that look forward in
time, which include everything other than historical information,
involve risks and uncertainties that may affect GT Biopharma, Inc.
(Nasdaq: GTBP) actual results of operations. Factors that could cause
actual results to vary include the size and growth of the market for
GT Biopharma, Inc. (Nasdaq: GTBP) products and/or services, the
company’s ability to fund its capital requirements in the near term
and long term, federal and state regulatory issues, pricing pressures,
etc. Future Giants is the publisher’s trademark. All trademarks used
in this advertisement other than Future Giants are the property of
their respective trademark holders and no endorsement by such owners
of the contents of this advertisement is made or implied. The
advertising agency and Future Giants are not affiliated, connected, or
associated with, and are not sponsored, approved, or originated by,
the trademark holders unless otherwise stated. No claim is made to any
rights in any third-party trademarks.

Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431

Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the
Markets. For more information about our privacy practices, please
review our Privacy Policy
[[link removed]]
or our Legal Notices.
[[link removed]]


Behind the Markets
[[link removed]]

_You are receiving this email because you are subscribed to Morning
Watchlist from Behind the Markets. If you no longer wish to receive
these partner emails, please unsubscribe here
[[link removed]]._